M 402 - Mestag Therapeutics
Alternative Names: M-402 Mestag TherapeuticsLatest Information Update: 05 Mar 2024
At a glance
- Originator Mestag Therapeutics
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Immune checkpoint protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation
Most Recent Events
- 15 Jan 2024 M 402 - Mestag Therapeutics is available for licensing as of 15 Jan 2024. https://www.mestagtherapeutics.com/science/#partners (Mestag Therapeutics pipeline, January 2024)
- 02 Jan 2024 Early research in Autoimmune disorders in USA (Parenteral), prior to January 2024 (Mestag Therapeutics pipeline, January 2024)
- 02 Jan 2024 Early research in Inflammation in USA (Parenteral), prior to January 2024 (Mestag Therapeutics pipeline, January 2024)